Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
By D. Brandsma, L. Stalpers, W. Taal, P. Sminia, M. J. van den Bent. The Lancet Oncology, 2008
1,080 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/15f80aadf9f26c305c9d9c7c4a41e492044b9808
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. (2016, background): “”(59,60) In addition, since the introduction of anti-angiogenic agents such as bevacizumab, the phenomenon of pseudoresponse complicates the assessment of treatment response using standard MRI alone.(59,61)”
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010, background): “This phenomenon, termed pseudoprogression, likely results from transiently increased permeability of the tumor vasculature from irradiation, which may be enhanced by temozolomide, and complicates the determination of tumor progression immediately after completion of radiotherapy.(26-30) Pseudoprogre”
- Cancer and Radiation Therapy: Current Advances and Future Directions (2012, background): “In the necrosis, TNF (alpha) -PARP-JNK-Caspases pathway [53] is involved and the MYC-INK4A-ARF-p53-p21 pathway has been implicated in senescence [54].”
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014, methodology): “The British study comparing RT alone with RT plus PCV showed no increase of survival with the addition of chemotherapy.(6) Local 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) wafer chemotherapy added to RT conferred a survival benefit of 13.”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Increased contrast enhancement and presumed tumour progression on imaging 4–12 weeks after the end of radiotherapy may be due to a reactive process following radiotherapy (pseudo-progression) [64, 65].”
- Immunotherapy Response Assessment in Neuro-Oncology (iRANO): A Report of the RANO Working Group (2015, methodology): “Subsequently, variations of RANO were refined for patients with lowgrade glioma17 and brain metastases.18 [4] A key cornerstone of RANO is guidance for the phenomenon of pseudoprogression which occurs in approximately 10-20% of newly diagnosed glioblastoma patients following TMZ/RT→TMZ.14,19-21 The ”